Cargando…

Eosinophil percentage elevation as a prognostic factor for overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor

BACKGROUND: We tried to investigate the prognostic significance of post-treatment eosinophil percentage(Eo %) in metastatic renal cell carcinoma(mRCC) patients undertaking sorafenib. RESULTS: The median OS for the entire sorafenib treatment period was 21.9 months (95% CI: 17.2–25.9 months). Of the 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Hong-Kai, Wan, Fang-Nin, Gu, Wei-Jie, Zhu, Yao, Dai, Bo, Shi, Guo-Hai, Zhang, Hai-Liang, Ye, Ding-Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356602/ https://www.ncbi.nlm.nih.gov/pubmed/27661105 http://dx.doi.org/10.18632/oncotarget.12126

Ejemplares similares

TYRO protein tyrosine kinase-binding protein predicts favorable overall survival in osteosarcoma and correlates with antitumor immunity
por: Xu, Hai-Ru, et al.
Publicado: (2022)

Prognostic significance of pseudocapsule status in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
por: Xi, Wei, et al.
Publicado: (2021)

The Impact of Renal Impairment on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors
por: Zhang, Haoran, et al.
Publicado: (2020)

Checkpoint molecule PD-1-assisted CD8(+) T lymphocyte count in tumor microenvironment predicts overall survival of patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors
por: Yao, Jiaxi, et al.
Publicado: (2018)

Eosinophil percentage as a new prognostic marker in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
por: Güner, Ahmet, et al.
Publicado: (2019)

Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor
por: Xia, Yu, et al.
Publicado: (2017)

Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
por: Catalano, Martina, et al.
Publicado: (2022)

Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation
por: Gu, Cheng-Yuan, et al.
Publicado: (2021)

Threonine and tyrosine kinase may serve as a prognostic biomarker for gallbladder cancer
por: Xie, Yuan, et al.
Publicado: (2017)

Prognostic significance of platelet–lymphocyte ratio in patients receiving first-line tyrosine kinase inhibitors for metastatic renal cell cancer
por: Park, Tae Ju, et al.
Publicado: (2016)

Prognostic Value of Neurotrophic Tyrosine Receptor Kinase Gene Fusions in Solid Tumors for Overall Survival: A Systematic Review and Meta-Analysis
por: Lassen, Ulrik, et al.
Publicado: (2023)

Influence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer Patients
por: Semeniuk-Wojtaś, Aleksandra, et al.
Publicado: (2016)

Acquired Hypothyroidism in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors
por: Wu, Jialu, et al.
Publicado: (2020)

Systemic Inflammatory Biomarkers Predict Survival of Patients Treated With Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
por: Wang, Zhaojuan, et al.
Publicado: (2023)

Biomarkers for tyrosine kinase inhibitors in renal cell cancer
por: Coupe, Nicholas, et al.
Publicado: (2012)

Requirement of Lyn and Syk tyrosine kinases for the prevention of apoptosis by cytokines in human eosinophils
Publicado: (1996)

Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study
por: Zhang, Hai-Liang, et al.
Publicado: (2015)

Immunoscore System for Predicting Clinical Outcome of Metastatic Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors
por: Yao, Jia-Xi, et al.
Publicado: (2018)

Hypertension as a prognostic factor in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis
por: Liu, Yu, et al.
Publicado: (2019)

Blood eosinophil percentage as a predictor of response to inhaled corticosteroid in bronchiectasis
por: Kwok, Wang Chun, et al.
Publicado: (2023)

Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma
por: Liu, Yang, et al.
Publicado: (2021)

Comparison of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma with rhabdoid and sarcomatoid differentiations
por: Wang, Kun, et al.
Publicado: (2023)

Lymphocyte percentage and platelet count correlate with the treatment outcome to tyrosine kinase inhibitors in epidermal growth factor receptor–mutated lung adenocarcinoma
por: Li, Chi-Cheng, et al.
Publicado: (2020)

Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: a systematic review and meta-analysis
por: Xu, Yawei, et al.
Publicado: (2019)

MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma
por: Catenacci, Daniel V. T., et al.
Publicado: (2016)

Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma
por: Ishihara, Hiroki, et al.
Publicado: (2017)

Impact of Prognostic Nutritional Index on Overall Survival for Patients with Metastatic Urothelial Carcinoma
por: Hsieh, Meng-Che, et al.
Publicado: (2018)

The prognostic effect of metastasis patterns on overall survival in organ metastatic lung adenocarcinoma
por: Tie, Xiaowei, et al.
Publicado: (2022)

Impacts of eosinophil percentage on prognosis acute type A aortic dissection patients
por: Shao, Yue, et al.
Publicado: (2022)

Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma
por: Wiecek, Witold, et al.
Publicado: (2016)

Artificial intelligence-based prediction of overall survival in metastatic renal cell carcinoma
por: Barkan, Ella, et al.
Publicado: (2023)

Multidisciplinary Team (MDT) Discussion Improves Overall Survival Outcomes for Metastatic Renal Cell Carcinoma Patients
por: Zeng, Yuhao, et al.
Publicado: (2023)

Survival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors
por: He, Liru, et al.
Publicado: (2020)

Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma
por: Busch, Jonas, et al.
Publicado: (2011)

Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
por: Lai, Yongchang, et al.
Publicado: (2018)

Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors
por: Janisch, Florian, et al.
Publicado: (2021)

Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor
por: Teishima, Jun, et al.
Publicado: (2021)

The impact of proton-pump inhibitors administered with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma
por: Buti, Sebastiano, et al.
Publicado: (2022)

Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival
por: Yu, Xiaoteng, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ln11a7blvd0ehtr2lekcnjsh8g